RSLS ReShape Lifesciences
- 0.1753
- +0.0083+4.97%
- 0.1743
- -0.0010-0.57%
ReShape Lifesciences News
Express News | ReShape Lifesciences Tweets 'Will #GLP1 Medications Replace #weightloss #surgery? According to ReShape CEO, Paul Hickey, via @InvestingCom, #GLP1s Are a Very Attractive Tool to Fight #obesity. However, Our ReShape Lap-Band Is Safe and Less Invasive'
ReShape Lifesciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Q4 2023 ReShape Lifesciences Inc Earnings Call
ReShape Lifesciences 2023 Rev $8.7M >RSLS
ReShape Lifesciences 2023 Rev $8.7M >RSLS
Express News | ReShape Lifesciences Expects 2024 Operating Expenses To Decrease By More Than 50% Compared to 2023; Reaffirming Commitment To Profitability
Express News | Reshape Lifesciences FY23 Sales $8.678M Miss $8.904M Estimate
Press Release: ReShape Lifesciences(R) Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a corporate strategic update.
Express News | ReShape Lifesciences Shares Are Trading Higher After the Company Received a Notice of Allowance for an Additional US Patent Related to an Intragastric Balloon System
Express News | ReShape Lifesciences Receives Notice Of Allowance For Additional US Patent Related To An Intragastric Balloon System
ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
PDF Version Patent Significantly Strengthens Intellectual Property PortfolioIRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences (Nasdaq: RSLS), the premier physician-led wei
Express News | ReShape Lifesciences Continues High Priority Search For Synergistic M&A Partner
Express News | ReShape Lifesciences Reaffirms Commitment To Profitability
Express News | ReShape Lifesciences Expects 2024 Operating Expenses Down 55.4% YoY
ReShape Lifesciences Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band 2.0 FLEX
PDF Version 2024 Operating Expenses Expected to Decrease by 55.4% Compared to 2023 Company Reaffirms Commitment to ProfitabilityHigh Priority Search for Synergistic M&A Partner ContinuesIRVINE, C
ReShape Lifesciences Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 FLEX
PDF Version FLEX Technology Designed to Enhance the Patient ExperienceSurgeon Training Underway for the Initial Launch of the Lap-Band 2.0 FLEXIRVINE, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) --
Express News | ReShape Lifesciences Posts On X "There Is Growing Consumer Awareness Of Medical #weightloss Generated By GLP-1s. Reshape Lifesciences Is Tapping Into This Market With Our Full Portfolio Of Weight Loss And Wellness Solutions"
Express News | ReShape Lifesciences Conducts Bariatric Fellows Training For Its Lap-Band System
ReShape Lifesciences Conducts Bariatric Fellows Training for Its Lap-Band System, Highlighting the Next-Generation Lap-Band 2.0 FLEX
PDF Version First Time Introduction of Lap-Band 2.0 FLEX to the Next Generation of SurgeonsIRVINE, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences (Nasdaq: RSLS), the premier phy
Short-term advantage becomes long-term advantage! Bernstein: Diet pills are expected to expand the bariatric surgery market
GLP-1 weight loss drugs are becoming more and more popular, and in the long run, they can expand the bariatric surgery market.
Anti-obesity Meds Can Expand the Market for Weight Loss Surgery: Bernstein
Analysis
Price Target
No Data
